Navigation Links
Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent
Date:10/24/2007

SAN FRANCISCO -- Researchers report positive results from a Phase I/II clinical trial of a novel anti-cancer drug which offers two modes of action. In 26 patients with advanced solid tumors, treatment with ECO-4601 is safe and well tolerated, including at doses yielding plasma concentrations above the expected therapeutic threshold, says Pierre Falardeau, Ph.D., chief operating officer at Thallion Pharmaceuticals in Montreal, Canada. Thallion has produced and tested ECO-4601 in association with the Segal Cancer Centre of McGill University.

Falardeau says that ECO-4601 has a unique mechanism of action comprising two distinct activities. It inhibits the RAS/MAPK intracellular signaling pathway, which is mutated in many cancer types, and which is the target of several approved cancer drugs such as Erbitux, Avastin, Tarceva, Nexavar, and Sutent. However, unlike these drugs, our preclinical experiments suggest that ECO-4601 acts at a unique point within the pathway, specifically at the level of RAS itself, Falardeau said.

As a target for inhibition, RAS presented researchers with a chance to affect the signaling pathway with less fear that loops in the pathway will compensate for its loss. Because RAS sits at a crossroad of multiple signaling pathways, targeting RAS may avoid some of the redundancies inherent in intracellular signaling, Falardeau said.

The agent also binds to the peripheral benzodiazepine receptor (PBR), which is over-expressed in multiple cancers. This intracellular PBR binding may allow the drug to accumulate within tumor cells, providing a more efficient way to inhibit the RAS/MAPK signaling pathway. In other words, ECO-4601 may preferentially target and accumulate within tumor cells because of the over-expression of the PBR, Falardeau said.

In addition to its safety, the researchers also found that, while blood concentrations of the drug increased linearly along with an increase in dosage, at the end o
'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. SARS-Free Taiwan to Mark End Phase of Global Fight
3. S. Africa AIDS in death phase
4. Spray on contraceptive clears Phase I trial
5. Phase 3 trials of two multi-kinase inhibitors against cancer
6. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
7. Phase II trails of new HIV vaccine to be held in South Africa
8. Phase 1 Drug Trials on Humans to Be Made Public
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
11. Cadila to Commence Phase I Clinical Trials On ZYH2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 A common approach to treating kidney ... not improve survival chances for people who suddenly developed ... the University of Pittsburgh School of Medicine. , Their ... , suggest acute hemodialysis, an aggressive method that is ... not provide a definitive benefit to the patient. , ...
(Date:8/20/2014)... (August 20, 2014) Research from Columbia University Medical ... in stomach cancer growth and that blocking nerve signals ... treatment for the disease. The study was conducted by ... with Duan Chen, MD, PhD, in Norway and is ... . , "Scientists have long observed that human and ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... Rosa, CA (PRWEB) August 20, 2014 The ... the 12 per diode panel band perfect spectrum that encompasses ... are most likely to use during photosynthesis. A key ... bands is that they almost exclusively reside between 440-480 on ... on the red side of the spectrum. The KIND LED ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Oct. 20 Strong new pledges of,commitment ... donors, government,officials, corporations, foundations and non-governmental organizations,today ... Deliver conference, which,sought to mobilize political will ... worldwide. More than 1,800 participants from ...
... YORK, Oct. 20 EmPower Research, LLC, a ... Consulting, launched its,first-ever study on the Indian Contract ... titled ,Indian Contract Research Industry, (CRO-nicles),captures the industry,s ... to the top line industry executives first hand. ...
... Following is a statement,by Linda A. Suydam, D.P.A., ... the recommendations issued today by the U.S.,Food and ... Committee. At a meeting this week, the joint ... medicines in children., "For decades, parents and ...
... Court, WILMINGTON, Del., Oct. 19 The following,statement ... W.Va., zinc,smelter class action lawsuit. The statement is to ... "We are extremely disappointed by the outcome of the ... unfairly punished for doing,the right thing for this property ...
... Mass., Oct. 19 LeMaitre Vascular,Inc. (Nasdaq: ... and implants for the treatment of peripheral vascular ... Annual Healthcare Conference on,Tuesday, November 6, 2007, in ... George W. LeMaitre, Chairman and Chief Executive Officer, ...
... the less the idea bothered her , , FRIDAY, Oct. ... the idea of childlessness than men, new research shows, ... how each gender views the pressures of parenthood. , ... and parenthood mean different things," said study author Tanya ...
Cached Medicine News:Health News:Women Deliver Conference Launches New Commitments 2Health News:EmPower Research Launches Indian CRO Industry Report 2Health News:Statement from the Consumer Healthcare Products Association on Today's Joint FDA Advisory Committee Recommendations Regarding Pediatric Over-the-Counter Cough and Cold Medicines 2Health News:DuPont Responds to Spelter, W.Va., Lawsuit Decision 2Health News:Childlessness Bothers Men More Than Women 2Health News:Childlessness Bothers Men More Than Women 3
(Date:8/20/2014)... Calif. , Aug. 20, 2014 The National ... Fernando Davila has been successfully treated for a ... by Dr, Anibal R. Gauto , Medical Director of ... at Eisenhower Medical Center in Rancho Mirage, California ... treatment pioneered by Dr. John Crew at Seton ...
(Date:8/20/2014)... , Aug. 20, 2014 Research and ... Report of Pralmorelin" report to their offering. ... providing comprehensive data on Pralmorelin globally and regionally ( ... North America , Latin America ... Pralmorelin This report focuses on three primary areas; ...
(Date:8/20/2014)... DUBLIN , Aug. 20, 2014 ... addition of the "Global Advanced Wound Care ... Geography) - Size, Share, Global Trends, Company Profiles, ... Forecast, 2013 - 2020" report to their ... "Global advanced wound care and closure market (types, ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... 2011 3-V Biosciences, Inc. announced today Stephen R. Brady ... (Logo:   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "Steve,s contributions have been ... at 3-V," said Merdad V. Parsey, MD, PhD, 3-V,s Chief ... we continue to build the 3-V team and advance the ...
... 2011 Awarepoint Corporation today announced it conducted its ... and User Group , Viewpoint | 2011, January 23-25, ... http://photos.prnewswire.com/prnh/20100127/LA44915LOGO ) At this exclusive Awarepoint event, ... with other hospitals to share information and use cases ...
Cached Medicine Technology:3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer 2Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights 2Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights 3Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: